Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges. - Wikidata - wikimedia - TriplyDB

Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges.

Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges.

http://www.wikidata.org/entity/Q36986507

about

Substrate-specific modulation of CYP3A4 activity by genetic variants of cytochrome P450 oxidoreductase Predicting risk of adverse drug reactions in older adults Individualized medicine enabled by genomics in Saudi Arabia Harvesting candidate genes responsible for serious adverse drug reactions from a chemical-protein interactome PharmGKB summary: very important pharmacogene information for RYR1 Pre-clinical immunotoxicity studies of nanotechnology-formulated drugs: Challenges, considerations and strategy A statin-dependent QTL for GATM expression is associated with statin-induced myopathy Association study between single-nucleotide polymorphisms in 199 drug-related genes and commonly measured quantitative traits of 752 healthy Japanese subjects Exploring off-targets and off-systems for adverse drug reactions via chemical-protein interactome--clozapine-induced agranulocytosis as a case study Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps)Genome wide analysis of drug-induced torsades de pointes: lack of common variants with large effect sizes Development of an adverse drug reaction risk assessment score among hospitalized patients with chronic kidney disease SePreSA: a server for the prediction of populations susceptible to serious adverse drug reactions implementing the methodology of a chemical-protein interactome Pharmacogenomic and clinical data link non-pharmacokinetic metabolic dysregulation to drug side effect pathogenesis Self-reported medication side effects in an older cohort living independently in the community--the Melbourne Longitudinal Study on Healthy Ageing (MELSHA): cross-sectional analysis of prevalence and risk factors.Towards a three-dimensional microfluidic liver platform for predicting drug efficacy and toxicity in humans.Donor-Dependent and Other Nondefined Factors Have Greater Influence on the Hepatic Phenotype Than the Starting Cell Type in Induced Pluripotent Stem Cell Derived Hepatocyte-Like Cells.Genealogical analysis as a new approach for the investigation of drug intolerance heritability.Predicting adverse drug reactions using publicly available PubChem BioAssay data Drug-induced liver injury in older adults.The Dark Side of the Moon - the Side Effects of Therapy in a Dynamic Era of Breast Cancer Management.In vitro platforms for evaluating liver toxicity.Predicting adverse side effects of drugs Idiosyncratic drug-induced liver injury and the role of inflammatory stress with an emphasis on an animal model of trovafloxacin hepatotoxicity A whole-genome association study of major determinants for allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients.The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update.The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy.Drug-induced long QT syndrome Zebrafish as model organisms for studying drug-induced liver injury Fusion of nonclinical and clinical data to predict human drug safety.Cerivastatin, genetic variants, and the risk of rhabdomyolysis.Population-based genome-wide association studies reveal six loci influencing plasma levels of liver enzymes.Personalizing health care: feasibility and future implications.Assessing the translatability of in vivo cardiotoxicity mechanisms to in vitro models using causal reasoning.Pharmacogenomics of adverse drug reactions: practical applications and perspectives.Genotype-environment interactions and their translational implications.Hepatic safety of antibiotics used in primary care Increased susceptibility to methotrexate-induced toxicity in nonalcoholic steatohepatitis.Risk factors for idiosyncratic drug-induced liver injury.Pharmacovigilance in oncology: evaluation of current practice and future perspectives.

P2860

Q24607331-F536B708-42E8-4BE1-9B6A-AE0E9FA201E4 Q26770379-48068655-697E-407E-82B2-E119EAB1BFEF Q26861059-0221CABE-B40B-45D9-8CDC-A82EB9607B11 Q27335598-A80D0105-4535-4E6B-AB52-78F062C62DCE Q28074804-BA706BBD-232F-4B4B-BA40-0633303854AE Q28081577-C7D3BBA1-1370-4CD7-9094-6673307A1AFE Q28218899-C566DFE8-3C9E-4C0C-AECE-9072D4C9DB08 Q28240269-67FA14D1-135C-4D6C-850A-3613D8305CA5 Q28477582-5FB3342E-D2C0-446F-BC7D-3B9B7B392E80 Q28478443-8F922067-7AC4-4178-89D0-94AA0B0EFDE0 Q28534878-10660A41-B0AA-4935-8EC6-B357782FAEF8 Q28538142-0315F38F-1F60-4DF1-BDDE-30013A5BCE7A Q30488528-E3A27B1A-5D5B-4666-9B7F-DBAC299B69CF Q30968128-8664D901-F447-4E4E-9CE6-48299F2B60E8 Q33600298-16D497E6-2F35-40DF-B4AF-EAE659BB3DEF Q33641648-EE198EF8-FD2C-4F30-9641-02CDE94C2B34 Q33722052-BFE60FC0-9C4C-4993-B88E-3CE2DE5DCBC1 Q33765249-18FF1773-7A32-49AF-B585-411205FC2AB3 Q33912477-493550C6-E7EE-46EC-ACA7-619434896D73 Q33949227-2678F679-E896-4509-B039-5AB594C3B9F3 Q34095802-F2D0C1C4-51C3-44ED-9221-EC534E57BE63 Q34143314-92E60D67-E9D4-4A29-98E1-9C8B92F5EC74 Q34173771-CD52E198-918E-443B-9274-FF64339CD005 Q34200596-A61AC88C-94B0-4A27-9D56-A60E16106089 Q34215820-9BE2B74E-0AA2-4BF7-8457-D17046BA0629 Q34216710-37D440B8-855A-49AD-8CDB-67EB52EA338F Q34276618-E656CD28-DF8D-4CDD-9847-029783A039D1 Q34358104-8F3D97EA-628F-48CA-99E8-42BAFE67AA96 Q34450956-76B1A879-FA71-43DD-97C0-ABCB78060DC6 Q34615323-6F68AE5E-4C10-49CD-A8AD-0C2CA75D70A8 Q34792178-F2D4B0EE-4DDD-44A0-B496-B4583270BBDD Q34861754-20C9182E-EF0B-48FF-9144-EF20226E5799 Q34938911-5F5F12F6-AEFD-4379-8BED-E7CFB7C44E8E Q34980120-9D2918EC-07F4-40A7-B94D-3C897A0CD60B Q34987138-3FD8C1A2-BFAA-4BDC-AB59-356D66447AAE Q35024668-0F6BE6AC-C585-4CA2-8DDD-E4448778E4FA Q35037383-624668B2-805B-4167-99FF-D37B06BF3E6D Q35102604-22415FDA-18FE-4745-A0B9-6EC0633732D2 Q35168108-7F4D0DEB-0C2C-4990-BA32-12F3AC99629A Q35183601-DB2EDCD3-0153-47A5-ABAB-28058AB7BDA7

P2860

Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges.

http://www.wikidata.org/entity/Q36986507

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

Identifying genetic risk facto ...... rrent progress and challenges.

@en

type

label

Identifying genetic risk facto ...... rrent progress and challenges.

@en

prefLabel

Identifying genetic risk facto ...... rrent progress and challenges.

@en

P1433

Q36986507-ECEC7C90-A40B-4B88-AA26-52B23604E2AB

P1476

Q36986507-3967DA5E-CCCB-4AD6-97BC-122200604381

P2093

Q36986507-29870996-5FAD-49A0-839D-1764F7E308BC

Q36986507-2F4E2045-8F51-452F-A799-6E1216C865CC

Q36986507-2F777015-9ED4-47E6-B637-62609F7A7326

Q36986507-8075333C-7F31-4683-84BD-2AB824A62596

Q36986507-CB2507C6-C5FD-4478-B5D6-7DB5E6C1912E

Q36986507-E40EA7E3-5066-45BF-8FA5-181DFC4F92DD

Q36986507-ED79E123-5729-498F-9B42-D2B7ABC669B7

P2860

Q36986507-03659B6B-B33B-471A-9884-BC67D535D400

Q36986507-036B36AB-5C9D-49EC-9001-58BC05F804C3

Q36986507-05A0AEE5-C23A-42EF-BBCE-7A533289DE27

Q36986507-05D097B5-2328-4788-910F-D81AF398C0BC

Q36986507-092C0CDD-7432-4C74-B803-22A676E97129

Q36986507-0CE365AC-5C2F-401C-BB62-06EF3803E576

Q36986507-0F299A9A-CFC3-4673-AE72-B59FF072234D

Q36986507-166F8284-AC1B-4A10-BCA3-8816400C9C05

Q36986507-1C8672E2-0C2F-4399-A117-2661051A01E9

Q36986507-1CA7BD14-B4A2-40E2-A720-AB3206AD2991

P2888

Q36986507-DBEC7D93-B184-4EFB-8EAC-306C9B55966F

P304

Q36986507-4979D8A5-249D-4BF2-ABA4-65612ED80C93

P31

Q36986507-AFBC6690-3A59-487C-B664-D31AEAA7DAD2

P356

Q36986507-39BDDDEF-2F7E-4CF6-AEDE-64E8E2FB8903

P433

Q36986507-2EC104F1-8DBB-44A3-8B7A-6BE808F95CB0

P478

Q36986507-68E7DAAC-820D-4348-93EB-396AB822F30D

P50

Q36986507-48EB08A0-0776-43BD-90CE-68A20B178200

P577

Q36986507-464A907C-9AE3-4377-9B4F-BCF42DCBF3E5

P5875

Q36986507-3953D332-285E-4DA5-A0D1-3AAD3F25B45A

P6179

Q36986507-F1C606B5-090E-4187-AB2C-4CCDCBDEF912

P698

Q36986507-891885E7-BAFF-41DB-BFEF-5CA77BE7882F

P932

Q36986507-6DA5B06D-D4FB-4514-BB46-801B5F756332

P356

P1433

Nature Reviews Drug Discovery

P1476

Identifying genetic risk facto ...... rrent progress and challenges.

@en

P2093

Dan M Roden

http://www.w3.org/2001/XMLSchema#string

Debbie W Lin

http://www.w3.org/2001/XMLSchema#string

Issam Zineh

http://www.w3.org/2001/XMLSchema#string

Kathleen M Giacomini

http://www.w3.org/2001/XMLSchema#string

Paul B Watkins

http://www.w3.org/2001/XMLSchema#string

Ronald M Krauss

http://www.w3.org/2001/XMLSchema#string

Russell A Wilke

http://www.w3.org/2001/XMLSchema#string

P2860

Genetic determinants of statin intolerance

MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia

Mutations in Kir2.1 cause the developmental and episodic electrical phenotypes of Andersen's syndrome

Defining the cellular phenotype of "ankyrin-B syndrome" variants: human ANK2 variants associated with clinical phenotypes display a spectrum of activities in cardiomyocytes

Ankyrin-B mutation causes type 4 long-QT cardiac arrhythmia and sudden cardiac death

Mutant caveolin-3 induces persistent late sodium current and is associated with long-QT syndrome

Positional cloning of a novel potassium channel gene: KVLQT1 mutations cause cardiac arrhythmias

A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel

A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome

SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome

P2888

P304

904-916

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NRD2423

http://www.w3.org/2001/XMLSchema#string

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P50

David Flockhart

P577

2007-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5874124

http://www.w3.org/2001/XMLSchema#string

P6179

1041544141

http://www.w3.org/2001/XMLSchema#string

P698

17971785

http://www.w3.org/2001/XMLSchema#string

P932

2763923

http://www.w3.org/2001/XMLSchema#string